{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:16:07Z","timestamp":1777619767624,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kirsehir Ahi Evran University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ellagic acid (EA) is a natural polyphenol noted for its antiproliferative and pro-apoptotic effects. This study investigates the impact of EA, alone or combined with cisplatin (CIS), on the expression of angiogenesis, apoptosis, metastasis, and chemoresistance-related genes and proteins in cisplatin-sensitive and -resistant MDA-MB-231 breast cancer cells. Cell viability was evaluated by cytotoxicity assay, while gene and protein expression levels were analyzed via qPCR and immunocytochemistry. Molecular docking was used to assess EA\u2019s binding affinity to target proteins. The IC\u2085\u2080 values of EA and CIS were 29 \u00b5M and 38.2 \u00b5M in cisplatin-sensitive MDA-MB-231 cells, and 49.5 \u00b5M and 80.2 \u00b5M in cisplatin-resistant cells, respectively. In both cell types, EA significantly decreased the expression of the ABCB1 and VEGF genes, especially at 24 and 48\u00a0h. EA alone and combined with CIS suppressed MMP2 and MMP9 expression across both cell types. Additionally, EA and CIS\u2009+\u2009EA treatments suppressed Bcl-2 expression and upregulated Bax expression. Immunocytochemical results aligned with gene expression data, demonstrating reduced protein levels. Molecular docking demonstrated strong binding of EA to Bax and MMP9. These results indicate that EA exerts notable anticancer activity by targeting genes associated with drug resistance, angiogenesis, apoptosis, and metastasis. The findings highlight EA\u2019s therapeutic potential in breast cancer treatment, alone or with CIS. Further detailed in vivo and clinical studies are needed to confirm these promising results.<\/jats:p>","DOI":"10.1007\/s12032-026-03270-1","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T11:29:45Z","timestamp":1772537385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the anticancer effects of ellagic acid and cisplatin in cisplatin-sensitive and -resistant MDA-MB-231 breast cancer cells"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7847-2898","authenticated-orcid":false,"given":"Gamze","family":"Turna Saltoglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9584-266X","authenticated-orcid":false,"given":"Serap","family":"Yalc\u0131n Azarkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7582-6235","authenticated-orcid":false,"given":"Gulistan Sanem","family":"Sar\u0131bas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-8505","authenticated-orcid":false,"given":"Seda","family":"Yalc\u0131nkaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"3","key":"3270_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3270_CR2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Th\u00fcrlimann B, Senn HJ. Strategies for subtypes \u2014 dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736\u201347.","journal-title":"Ann Oncol"},{"issue":"4","key":"3270_CR3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041320","volume":"15","author":"B Kinnel","year":"2023","unstructured":"Kinnel B, Singh SK, Oprea-Ilies G, Singh R. Targeted therapy and mechanisms of drug resistance in breast cancer. Cancers (Basel). 2023;15(4):1320.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"3270_CR4","first-page":"97","volume":"11","author":"A Brown","year":"2019","unstructured":"Brown A, Kumar S, Tchounwou PB. Cisplatin-based chemotherapy of human cancers. J Cancer Sci Ther. 2019;11(4):97.","journal-title":"J Cancer Sci Ther"},{"issue":"47","key":"3270_CR5","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","volume":"22","author":"ZH Siddik","year":"2003","unstructured":"Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265\u201379.","journal-title":"Oncogene"},{"issue":"1","key":"3270_CR6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10555-024-10172-z","volume":"43","author":"GR Bhat","year":"2024","unstructured":"Bhat GR, Sethi I, Sadida HQ, Rah B, Mir R, Algehainy N, et al. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Cancer Metastasis Rev. 2024;43(1):197\u2013228.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"3270_CR7","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph20031708","volume":"20","author":"I Llamas-Ramos","year":"2023","unstructured":"Llamas-Ramos I, Alvarado-Omenat JJ, Rodrigo-Reguil\u00f3n M, Llamas-Ramos R. Quality of life and side effects management in cancer treatment - a cross sectional study. Int J Environ Res Public Health. 2023;20(3):1708.","journal-title":"Int J Environ Res Public Health"},{"key":"3270_CR8","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1007\/s00204-024-03786-3","volume":"98","author":"S Ghosh","year":"2024","unstructured":"Ghosh S, Das SK, Sinha K, Ghosh B, Sen K, et al. The emerging role of natural products in cancer treatment. Arch Toxicol. 2024;98:2353\u201391.","journal-title":"Arch Toxicol"},{"issue":"6","key":"3270_CR9","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/bph.14816","volume":"177","author":"SR Lin","year":"2020","unstructured":"Lin SR, Chang CH, Hsu CF, Tsai MJ, Cheng H, Leong MK, et al. Natural compounds as potential adjuvants to cancer therapy: preclinical evidence. Br J Pharmacol. 2020;177(6):1409\u201323.","journal-title":"Br J Pharmacol"},{"issue":"1\u20132","key":"3270_CR10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0021-9673(00)00414-3","volume":"896","author":"Y Amakura","year":"2000","unstructured":"Amakura Y, Okada M, Tsuji S, Tonogai Y. High-performance liquid chromatographic determination with photodiode array detection of ellagic acid in fresh and processed fruits. J Chromatogr A. 2000;896(1\u20132):87\u201393.","journal-title":"J Chromatogr A"},{"issue":"4","key":"3270_CR11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40487-024-00296-1","volume":"12","author":"A Chauhan","year":"2024","unstructured":"Chauhan A, Yadav M, Chauhan R, Basniwal RK, Pathak VM, Ranjan A, et al. Exploring the potential of ellagic acid in gastrointestinal cancer prevention: recent advances and future directions. Oncol Ther. 2024;12(4):685\u201399.","journal-title":"Oncol Ther"},{"issue":"11","key":"3270_CR12","doi-asserted-by":"crossref","DOI":"10.3390\/nu8110744","volume":"8","author":"C Ceci","year":"2016","unstructured":"Ceci C, Tentori L, Atzori MG, Lacal PM, Bonanno E, Scimeca M, et al. Ellagic acid inhibits bladder cancer invasiveness and in vivo tumor growth. Nutrients. 2016;8(11):744.","journal-title":"Nutrients"},{"key":"3270_CR13","volume":"165","author":"G Lu","year":"2023","unstructured":"Lu G, Wang X, Cheng M, Wang S, Ma K. The multifaceted mechanisms of ellagic acid in the treatment of tumors: state-of-the-art. Biomed Pharmacother. 2023;165:115132.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"3270_CR14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21103526","volume":"21","author":"M Yousuf","year":"2020","unstructured":"Yousuf M, Shamsi A, Khan P, Shahbaaz M, AlAjmi MF, Hussain A, et al. Ellagic acid controls cell proliferation and induces apoptosis in breast cancer cells via inhibition of cyclin-dependent kinase 6. Int J Mol Sci. 2020;21(10):3526.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3270_CR15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.21037\/tcr-20-2446","volume":"10","author":"JY Kim","year":"2021","unstructured":"Kim JY, Choi YJ, Kim HJ. Determining the effect of ellagic acid on the proliferation and migration of pancreatic cancer cell lines. Transl Cancer Res. 2021;10(1):424\u201333.","journal-title":"Transl Cancer Res"},{"key":"3270_CR16","volume":"81","author":"X Ni","year":"2023","unstructured":"Ni X, Shang FS, Wang TF, Wu DJ, Chen DG, Zhuang B. Ellagic acid induces apoptosis and autophagy in colon cancer through the AMPK\/mTOR pathway. Tissue Cell. 2023;81:102032.","journal-title":"Tissue Cell"},{"issue":"5","key":"3270_CR17","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.7314\/APJCP.2013.14.5.2859","volume":"14","author":"P Pitchakarn","year":"2013","unstructured":"Pitchakarn P, Chewonarin T, Ogawa K, Suzuki S, Asamoto M, Takahashi S, et al. Ellagic acid inhibits migration and invasion by prostate cancer cell lines. Asian Pac J Cancer Prev. 2013;14(5):2859\u201363.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"20","key":"3270_CR18","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s00018-008-8111-5","volume":"65","author":"H Lage","year":"2008","unstructured":"Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci. 2008;65(20):3145\u201367.","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"3270_CR19","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4155\/fmc.15.36","volume":"7","author":"RJ Ferreira","year":"2015","unstructured":"Ferreira RJ, dos Santos DJ, Ferreira MJ. P-glycoprotein and membrane roles in multidrug resistance. Future Med Chem. 2015;7(7):929\u201346.","journal-title":"Future Med Chem"},{"key":"3270_CR20","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/476974","volume":"2014","author":"K Katayama","year":"2014","unstructured":"Katayama K, Noguchi K, Sugimoto Y. Regulations of P-glycoprotein\/ABCB1\/MDR1 in human cancer cells. New J Sci. 2014;2014:476974.","journal-title":"New J Sci"},{"issue":"1","key":"3270_CR21","first-page":"14","volume":"1","author":"GW Prager","year":"2012","unstructured":"Prager GW, Poettler M, Unseld M, Zielinski CC. Angiogenesis in cancer: anti-VEGF escape mechanisms. Transl Lung Cancer Res. 2012;1(1):14\u201325.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"3270_CR22","doi-asserted-by":"crossref","DOI":"10.3390\/biom15010035","volume":"15","author":"A Shoari","year":"2024","unstructured":"Shoari A, Ashja Ardalan A, Dimesa AM, Coban MA. Targeting invasion: the role of MMP-2 and MMP-9 inhibition in colorectal cancer therapy. Biomolecules. 2024;15(1):35.","journal-title":"Biomolecules"},{"issue":"2","key":"3270_CR23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2174\/1871520621666210727105431","volume":"22","author":"FK Ata","year":"2022","unstructured":"Ata FK, Yalcin S. The cisplatin, 5-fluorouracil, irinotecan, and gemcitabine treatment in resistant 2D and 3D model triple negative breast cancer cell line: ABCG2 expression data. Anticancer Agents Med Chem. 2022;22(2):371\u20137.","journal-title":"Anticancer Agents Med Chem"},{"issue":"4","key":"3270_CR24","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/adt.2011.391","volume":"10","author":"L Huyck","year":"2012","unstructured":"Huyck L, Ampe C, Van Troys M. The XTT cell proliferation assay applied to cell layers embedded in three-dimensional matrix. Assay Drug Dev Technol. 2012;10(4):382\u201392.","journal-title":"Assay Drug Dev Technol"},{"issue":"2","key":"3270_CR25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455\u201361.","journal-title":"J Comput Chem"},{"key":"3270_CR26","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.716466","volume":"8","author":"S Murail","year":"2021","unstructured":"Murail S, de Vries SJ, Rey J, Moroy G, Tuff\u00e9ry P. SeamDock: an interactive and collaborative online docking resource to assist small compound molecular docking. Front Mol Biosci. 2021;8:716466.","journal-title":"Front Mol Biosci"},{"key":"3270_CR27","volume-title":"samuelmurail\/docking_py: Docking_py, a python library for ligand protein Docking [Internet]","author":"P Tuff\u00e9ry","year":"2020","unstructured":"Tuff\u00e9ry P, Murail S. samuelmurail\/docking_py: Docking_py, a python library for ligand protein Docking [Internet]. Paris: Zenodo; 2020."},{"issue":"11","key":"3270_CR28","doi-asserted-by":"crossref","DOI":"10.3390\/nu10111756","volume":"10","author":"C Ceci","year":"2018","unstructured":"Ceci C, Lacal PM, Tentori L, De Martino MG, Miano R, Graziani G. Experimental evidence of the antitumor, antimetastatic and antiangiogenic activity of ellagic acid. Nutrients. 2018;10(11):1756.","journal-title":"Nutrients"},{"key":"3270_CR29","volume":"31","author":"Y Goyal","year":"2022","unstructured":"Goyal Y, Koul A, Ranawat P. Ellagic acid modulates cisplatin toxicity in DMH induced colorectal cancer: studies on membrane alterations. Biochem Biophys Rep. 2022;31:101319.","journal-title":"Biochem Biophys Rep"},{"issue":"12","key":"3270_CR30","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13122062","volume":"13","author":"K Singh","year":"2021","unstructured":"Singh K, Tarapcs\u00e1k S, Gy\u00f6ngy Z, Ritter Z, Batta G, Bosire R, et al. Effects of polyphenols on P-glycoprotein (ABCB1) activity. Pharmaceutics. 2021;13(12):2062.","journal-title":"Pharmaceutics"},{"key":"3270_CR31","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.wneu.2019.08.257","volume":"132","author":"A \u00c7etin","year":"2019","unstructured":"\u00c7etin A, Biltekin B, Degirmencioglu S. Ellagic acid enhances the antitumor efficacy of bevacizumab in an in vitro glioblastoma model. World Neurosurg. 2019;132:e59\u201365.","journal-title":"World Neurosurg"},{"issue":"3","key":"3270_CR32","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10549-012-1977-9","volume":"134","author":"N Wang","year":"2012","unstructured":"Wang N, Wang ZY, Mo SL, Loo TY, Wang DM, Luo HB, et al. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. Breast Cancer Res Treat. 2012;134(3):943\u201355.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"3270_CR33","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3390\/cancers5020726","volume":"5","author":"L Vanella","year":"2013","unstructured":"Vanella L, Di Giacomo C, Acquaviva R, Barbagallo I, Li Volti G, Cardile V, et al. Effects of ellagic acid on angiogenic factors in prostate cancer cells. Cancers (Basel). 2013;5(2):726\u201338.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"3270_CR34","doi-asserted-by":"crossref","first-page":"7489","DOI":"10.1007\/s11033-023-08664-2","volume":"50","author":"M Jalalpour Choupanan","year":"2023","unstructured":"Jalalpour Choupanan M, Shahbazi S, Reiisi S. Naringenin in combination with quercetin\/fisetin shows synergistic anti-proliferative and migration reduction effects in breast cancer cell lines. Mol Biol Rep. 2023;50(9):7489\u2013500.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"3270_CR35","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.3892\/ijo.2015.2870","volume":"46","author":"HS Chen","year":"2015","unstructured":"Chen HS, Bai MH, Zhang T, Li GD, Liu M. Ellagic acid induces cell cycle arrest and apoptosis through TGF-\u03b2\/Smad3 signaling pathway in human breast cancer MCF-7 cells. Int J Oncol. 2015;46(4):1730\u20138.","journal-title":"Int J Oncol"},{"issue":"6","key":"3270_CR36","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1080\/01635581.2017.1339811","volume":"69","author":"V Ahire","year":"2017","unstructured":"Ahire V, Kumar A, Mishra KP, Kulkarni G. Ellagic acid enhances apoptotic sensitivity of breast cancer cells to \u03b3-radiation. Nutr Cancer. 2017;69(6):904\u201310.","journal-title":"Nutr Cancer"},{"issue":"16","key":"3270_CR37","volume":"23","author":"SM Badr-Eldin","year":"2022","unstructured":"Badr-Eldin SM, Aldawsari HM, Fahmy UA, Ahmed OAA, Alhakamy NA, Al-Hejaili OD, et al. Optimized apamin-mediated nano-lipidic carrier potentially enhances the cytotoxicity of ellagic acid against human breast cancer cells. Int J Mol Sci. 2022;23(16):9440.","journal-title":"Int J Mol Sci"},{"issue":"15","key":"3270_CR38","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.7150\/jca.29738","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang Y, Ren F, Li B, Song Z, Chen P, Ouyang L. Ellagic acid exerts antitumor effects via the PI3K signaling pathway in endometrial cancer. J Cancer. 2019;10(15):3303\u201314.","journal-title":"J Cancer"},{"issue":"23","key":"3270_CR39","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.3748\/wjg.14.3672","volume":"14","author":"M Edderkaoui","year":"2008","unstructured":"Edderkaoui M, Odinokova I, Ohno I, Gukovsky I, Go VL, Pandol SJ, et al. Ellagic acid induces apoptosis through Inhibition of nuclear factor kappa B in pancreatic cancer cells. World J Gastroenterol. 2008;14(23):3672\u201380.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"3270_CR40","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1080\/15384047.2017.1394542","volume":"18","author":"H Liu","year":"2017","unstructured":"Liu H, Zeng Z, Wang S, Li T, Mastriani E, Li QH, et al. Main components of pomegranate, ellagic acid and luteolin, inhibit metastasis of ovarian cancer by down-regulating MMP2 and MMP9. Cancer Biol Ther. 2017;18(12):990\u20139.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"3270_CR41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4274\/cjms.2023.2022-49","volume":"8","author":"GS Sar\u0131ba\u015f","year":"2023","unstructured":"Sar\u0131ba\u015f GS, Salto\u011flu GT, Azarkan SY, Dizakar \u00d6A, Yal\u00e7\u0131nkaya S. Effects of irinotecan (CPT-11), ellagic acid and combination of both on HeLa cells in 2D and 3D culture. Cyprus J Med Sci. 2023;8(3):173\u201383.","journal-title":"Cyprus J Med Sci"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03270-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03270-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03270-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:07:08Z","timestamp":1776344828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03270-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["3270"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03270-1","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"162"}}